Dapagliflozin (Forxiga)
Sponsors
AstraZeneca, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Assiut University, University Malaysia Sarawak, Hawler Medical University
Conditions
Anthracyclines-Induced CardiotoxicityCardiotoxicityCoronary Artery DiseaseDiabetes Mellitus, Type 2Metabolic Associated Fatty Liver DiseaseObstructive Sleep ApneaPreDiabetesPulmonary Hypertension
Phase 1
An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions
CompletedNCT02722239
Start: 2016-03-30End: 2016-05-05Updated: 2018-02-19
Dapagliflozin in Mangement of Pulmonary Hypertension Patients
Not yet recruitingNCT06612086
Start: 2024-10-25End: 2026-10-10Target: 70Updated: 2024-10-29
Phase 2
Phase 3
Phase 4
Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study
Active, not recruitingNCT05782972
Start: 2023-03-11End: 2025-12-31Updated: 2025-03-03
Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes
RecruitingNCT07254572
Start: 2025-07-10End: 2029-08-01Target: 300Updated: 2025-11-28